Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Renal Lifecycle Trial: Effect of dapagliflozin on renal and cardiovascular outcomes in severe chronic kidney disease
2023-508389-13-00Phase 3Authorised
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD), heart failure (HF) and cardiac morbidity comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Primary composite endpoint. Planned start Nov 2022; status: authorised.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)heart failure (HF)cardiac morbidity
Beyond the preview
Go deeper on 2023-508389-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508389-13-00.